Nicholas Y Tan1, Lindsey R Sangaralingham2, S Jeson Sangaralingham1, Xiaoxi Yao3, Nilay D Shah4, Shannon M Dunlay5. 1. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. 2. The Robert and Patricia E. Kern Center for the Sciences of Healthcare Delivery, Mayo Clinic, Rochester, Minnesota. 3. The Robert and Patricia E. Kern Center for the Sciences of Healthcare Delivery, Mayo Clinic, Rochester, Minnesota; Division of Health Care Policy and Research in the Department of Health Services Research, Mayo Clinic, Rochester, Minnesota. 4. The Robert and Patricia E. Kern Center for the Sciences of Healthcare Delivery, Mayo Clinic, Rochester, Minnesota; Division of Health Care Policy and Research in the Department of Health Services Research, Mayo Clinic, Rochester, Minnesota; OptumLabs, Cambridge, Massachusetts. 5. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota; The Robert and Patricia E. Kern Center for the Sciences of Healthcare Delivery, Mayo Clinic, Rochester, Minnesota. Electronic address: dunlay.shannon@mayo.edu.
Abstract
OBJECTIVES: This paper aims to compare the effectiveness of sacubitril-valsartan and angiotensin-converting enzyme inhibitor (ACE)/angiotensin receptor blocker (ARB) in systolic heart failure (HF). BACKGROUND: Sacubitril-valsartan reduced risks of death and hospitalization for HF versus enalapril in ambulatory patients with HF and reduced ejection fraction in the PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin Inhibitor with Angiotensin Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in HF) trial. However, the comparative effectiveness of sacubitril-valsartan and ACE/ARB in patients treated in routine clinical practice is unclear. METHODS: We identified patients with systolic HF in a U.S. administrative claims database treated with sacubitril-valsartan or ACE/ARB from July 1, 2015, to February 2, 2018. One-to-one propensity score matching was used to balance patients on 29 clinical variables. Cox models were used to compare outcomes between treatment groups. RESULTS: A total of 7,893 matched pairs were included; mean (SD) follow-up was 6.3 (5.4) months. Sacubitril-valsartan was associated with lower risks of all-cause mortality or all-cause hospitalization (hazard ratio [HR]: 0.86, 95% confidence interval (CI): 0.81 to 0.91; p < 0.001), all-cause mortality (HR: 0.80, 95% CI: 0.66 to 0.97; p = 0.027), and all-cause hospitalization (HR: 0.86, 95% CI: 0.80 to 0.91; p < 0.001), but not HF hospitalization (HR: 1.07, 95% CI: 0.96 to 1.19; p = 0.26). A lower risk of the primary outcome with sacubitril-valsartan was observed in white patients (HR: 0.83, 95% CI: 0.76 to 0.90) but not black patients (21% of population, HR: 1.00, 95% CI: 0.88 to 1.15; interaction p = 0.032). No statistically significant differences in treatment response by sex or age were observed. CONCLUSIONS: Sacubitril-valsartan was associated with lower risks of death and hospitalization compared with ACE/ARB in a heterogeneous cohort of patients with systolic HF. However, our finding that outcomes with sacubitril-valsartan and ACE/ARBs were similar in black patients warrants further evaluation.
OBJECTIVES: This paper aims to compare the effectiveness of sacubitril-valsartan and angiotensin-converting enzyme inhibitor (ACE)/angiotensin receptor blocker (ARB) in systolic heart failure (HF). BACKGROUND:Sacubitril-valsartan reduced risks of death and hospitalization for HF versus enalapril in ambulatory patients with HF and reduced ejection fraction in the PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin Inhibitor with Angiotensin Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in HF) trial. However, the comparative effectiveness of sacubitril-valsartan and ACE/ARB in patients treated in routine clinical practice is unclear. METHODS: We identified patients with systolic HF in a U.S. administrative claims database treated with sacubitril-valsartan or ACE/ARB from July 1, 2015, to February 2, 2018. One-to-one propensity score matching was used to balance patients on 29 clinical variables. Cox models were used to compare outcomes between treatment groups. RESULTS: A total of 7,893 matched pairs were included; mean (SD) follow-up was 6.3 (5.4) months. Sacubitril-valsartan was associated with lower risks of all-cause mortality or all-cause hospitalization (hazard ratio [HR]: 0.86, 95% confidence interval (CI): 0.81 to 0.91; p < 0.001), all-cause mortality (HR: 0.80, 95% CI: 0.66 to 0.97; p = 0.027), and all-cause hospitalization (HR: 0.86, 95% CI: 0.80 to 0.91; p < 0.001), but not HF hospitalization (HR: 1.07, 95% CI: 0.96 to 1.19; p = 0.26). A lower risk of the primary outcome with sacubitril-valsartan was observed in white patients (HR: 0.83, 95% CI: 0.76 to 0.90) but not black patients (21% of population, HR: 1.00, 95% CI: 0.88 to 1.15; interaction p = 0.032). No statistically significant differences in treatment response by sex or age were observed. CONCLUSIONS:Sacubitril-valsartan was associated with lower risks of death and hospitalization compared with ACE/ARB in a heterogeneous cohort of patients with systolic HF. However, our finding that outcomes with sacubitril-valsartan and ACE/ARBs were similar in black patients warrants further evaluation.
Authors: Paul A Heidenreich; Gregg C Fonarow; Khadijah Breathett; Corrine Y Jurgens; Barbara A Pisani; Bunny J Pozehl; John A Spertus; Kenneth G Taylor; Jennifer T Thibodeau; Clyde W Yancy; Boback Ziaeian Journal: Circ Cardiovasc Qual Outcomes Date: 2020-11-02
Authors: Nicholas Y Tan; Yihong Deng; Xiaoxi Yao; Lindsey R Sangaralingham; Nilay D Shah; Andrew D Rule; John C Burnett; Shannon M Dunlay; S Jeson Sangaralingham Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2021-02-15
Authors: Amitabh C Pandey; Derek Jer; Ruth S Kuo; David H Yoo; Antonio Christophy; Rajeev C Mohan; Ajay V Srivastava; James Thomas Heywood Journal: Clin Cardiol Date: 2020-12-05 Impact factor: 2.882
Authors: Swathi Pathadka; Vincent K C Yan; Xue Li; Gary Tse; Eric Y F Wan; Hayden Lau; Wallis C Y Lau; David C W Siu; Esther W Chan; Ian C K Wong Journal: Front Cardiovasc Med Date: 2021-01-20
Authors: Rafał Niemiec; Irmina Morawska; Maria Stec; Wiktoria Kuczmik; Andrzej S Swinarew; Arkadiusz Stanula; Katarzyna Mizia-Stec Journal: Int J Environ Res Public Health Date: 2022-02-13 Impact factor: 3.390
Authors: Paul A Heidenreich; Gregg C Fonarow; Khadijah Breathett; Corrine Y Jurgens; Barbara A Pisani; Bunny J Pozehl; John A Spertus; Kenneth G Taylor; Jennifer T Thibodeau; Clyde W Yancy; Boback Ziaeian Journal: J Am Coll Cardiol Date: 2020-11-02 Impact factor: 24.094
Authors: Stephen Y Wang; Javier Valero-Elizondo; Hyeon-Ju Ali; Ambarish Pandey; Miguel Cainzos-Achirica; Harlan M Krumholz; Khurram Nasir; Rohan Khera Journal: J Am Heart Assoc Date: 2021-05-16 Impact factor: 5.501